News

28 April 2008, Cambridge, UK - BioWisdom Ltd (BioWisdom), a market leader in delivering healthcare intelligence to the pharmaceutical industry, today announces the release of version 6 of its award-winning OmniViz software and a partnership with CambridgeSoft.

OmniViz visual intelligence software is a complete solution for all data visualization, uniquely supporting the analysis of text, numeric and categorical information. Version 6 incorporates a number of enhancements, such as the ability to identify data columns by attributes and sort them according to these specific attributes. In addition v6 presents new statistical models for analysing subsets of data and enhanced searching and highlighting tools.

6 March 2008, Cambridge, UK - BioWisdom Ltd (BioWisdom), a market leader in delivering healthcare intelligence to the pharmaceutical industry, today announced that Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) has extended its Collaboration Agreement with OmniViz, Inc., extending J&J PRD's license rights to OmniViz software for information visualization and data mining.

"We are delighted with J&J PRD's decision to continue its relationship with OmniViz" said Michael Stapleton, BioWisdom's CBO. "As our investment in the creation of truly ontology powered applications like OmniViz grows, so does the importance of our strategic collaborators with real world use cases and validation."
OmniViz visual intelligence software is a complete solution for all data visualization, uniquely supporting the analysis of text, numeric and categorical information.

19 February 2008, Cambridge, UK - BioWisdom Ltd, the market leader in ontology-powered intelligence solutions for the healthcare industry, today announced a three-year agreement with Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, NV (J&JPRD).

Under the terms of the agreement, J&JPRD will become the second partner for BioWisdom's Safety Intelligence Program (SIP). The first partnership was formed with AstraZeneca. The financial details of the deal have not been disclosed.

The Safety Intelligence Program applies BioWisdom's Sofia technology to deliver a specialist medical search system to support drug safety risk assessment at all stages of pharmaceutical R&D. Through the partnership, J&JPRD joins BioWisdom's SIP board.

BioWisdom Joins InforSense Open Workflow Partner Network

London, UK and Cambridge, MA, February 6, 2008 - InforSense Ltd., the leading provider of embedded enterprise intelligence, today announced that it will integrate BioWisdom's SRS bioinformatics software with InforSense's workflow analytics platform, enabling customers to automate and improve their bioinformatics analysis. As part of the agreement BioWisdom will join the InforSense Open Workflow Partner Network.

"SRS provides a specialist healthcare search interface to hundreds of databases and has built in analysis tools which users will now be able to leverage in the InforSense KDE platform," said Dr Michael R Stapleton, Chief Business Officer, BioWisdom. "The integration is a result of strong customer requests for the two systems to be used together"

31 January 2008, Cambridge, UK - BioWisdom Ltd (BioWisdom), a leader in the provision of healthcare software and healthcare intelligence for the pharmaceutical industry, today announces the release of its SRS 3D technology as free software under the GNU General Public License version two (GPLv2).

SRS is a proven, scalable and robust data integration platform that provides fast access to diverse life sciences information including genetic, protein, expression, pathway, molecular and clinical data from public and proprietary sources, regardless of data format. SRS is the market leader for bioinformatics data integration, providing global bioinformatics platforms to pharmaceutical companies including GSK, Eli Lilly, Merck and Co, and Pfizer. SRS 3D is a module of Biowisdom's SRS system that enables the integration and display of sequences and annotations together with 3D structures. The details are available at http://www.SRS3D.org, a site hosted by the European Molecular Biology Laboratory (EMBL).

31 January 2008, Cambridge, UK - BioWisdom Ltd (BioWisdom), a leader in the provision of healthcare software and healthcare intelligence for the pharmaceutical industry, today announces the release of SRS version 8.3.

SRS 8.3 provides new functionality, improved user interface and support for the latest hardware and software platforms. Improvements in the new version include:

BioWisdom has launched an exclusive program that gives access to its OmniViz visualization and analysis software to academics and not-for-profit organisations at a heavily discounted price of $999.

Julie Barnes PhD, CSO of BioWisdom Ltd, the market leader in delivering healthcare intelligence to the pharmaceutical industry, today presented at the Drug Information Association (DIA) conference in Madrid. The DIA conference is considering Pharmacovigilance (PV) and Clinical Data Management (CDM) and ways of managing safety data more effectively, with a specific focus on embracing new technologies for improving the processing and interpretation of adverse events.

BioWisdom Limited (BioWisdom), a leader in the provision of healthcare software and intelligence to the pharmaceutical industry, today announced plans to expand its global sales and marketing activities under the direction of Michael Stapleton Ph.D. Dr. Stapleton has more than 20 years experience in the field of scientific software and informatics. He was most recently Vice President of Global Marketing and eBusiness at Invitrogen (Nasdaq: IVGN) responsible for the industry-leading web, bioinformatics and eCommerce activities. Prior to Invitrogen, Dr. Stapleton spent 11 years at Accelrys (Nasdaq: ACCL). In particular, as Chief Operating Officer, he was responsible for launching Accelrys in 2001 as a result of the integration of Molecular Simulations, Synopsys, Oxford Molecular Group and Genetics Computer Group. Dr. Stapleton has a Ph.D. in chemistry and has undertaken research at Cornell University and British Petroleum. "BioWisdom’s unique selling point has been its ability to work alongside the scientific community and design bespoke intelligence systems.

BioWisdom Limited (BioWisdom), a leader in the provision of healthcare software and healthcare intelligence for the pharmaceutical industry, today announced that Pfizer has signed a further agreement for a BioWisdom KnowledgeScan™ project to assess the market opportunity, potential strategy and clinical trial design for a particular class of compounds. BioWisdom KnowledgeScan™ projects are powered by a suite of state-of-the art technologies to provide unbiased and comprehensive Intelligence to support healthcare-related decision-making for project teams. The service provides a rapid and systematic analysis of large amounts of data and is carried out by an experienced team of healthcare analysts. “We are delighted that Pfizer continue to gain value from our services and we look forward to working closely with them on yet another project.” said Julie Barnes, CSO of BioWisdom.